Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor

被引:234
作者
Noyan, F. [1 ,2 ]
Zimmermann, K. [1 ]
Hardtke-Wolenski, M. [1 ]
Knoefel, A. [3 ]
Schulde, E. [1 ]
Geffers, R. [4 ]
Hust, M. [5 ]
Huehn, J. [6 ]
Galla, M. [7 ]
Morgan, M. [7 ]
Jokuszies, A. [8 ]
Manns, M. P. [1 ]
Jaeckel, E. [1 ,2 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[2] Hannover Med Sch, Integrated Res & Treatment Ctr, Transplantat IFB Tx, Hannover, Germany
[3] Hannover Med Sch, Dept Cardiothorac Transplantat & Vasc Surg, Hannover, Germany
[4] Helmholtz Ctr Infect Res, RG Genome Analyt, Braunschweig, Germany
[5] Tech Univ Carolo Wilhelmina Braunschweig, Dept Biotechnol, Inst Biochem Biotechnol & Bioinformat, Braunschweig, Germany
[6] Helmholtz Ctr Infect Res, Dept Expt Immunol, Braunschweig, Germany
[7] Hannover Med Sch, Inst Expt Haematol, Hannover, Germany
[8] Hannover Med Sch, Dept Plast Aesthet Hand & Reconstruct Surg, Hannover, Germany
关键词
basic (laboratory) research; science; translational research; immunobiology; immunosuppression; immune modulation; tissue (nonvascularized) transplantation; tolerance; tolerance: experimental; T cell biology; gene therapy; TRANSPLANTATION TOLERANCE; LIVER-TRANSPLANTATION; IN-VIVO; INSTABILITY; GENERATION; ENRICHMENT; FREQUENCY; THERAPY; DISEASE;
D O I
10.1111/ajt.14175
中图分类号
R61 [外科手术学];
学科分类号
摘要
CD4(+)CD25(high)FOXP3(+) regulatory T cells (Tregs) are involved in graft-specific tolerance after solid organ transplantation. However, adoptive transfer of polyspecific Tregs alone is insufficient to prevent graft rejection even in rodent models, indicating that graft-specific Tregs are required. We developed a highly specific chimeric antigen receptor that recognizes the HLA molecule A*02 (referred to as A2-CAR). Transduction into natural regulatory T cells (nTregs) changes the specificity of the nTregs without alteration of their regulatory phenotype and epigenetic stability. Activation of nTregs via the A2-CAR induced proliferation and enhanced the suppressor function of modified nTregs. Compared with nTregs, A2-CAR Tregs exhibited superior control of strong allospecific immune responses in vitro and in humanized mouse models. A2-CAR Tregs completely prevented rejection of allogeneic target cells and tissues in immune reconstituted humanized mice in the absence of any immunosuppression. Therefore, these modified cells have great potential for incorporation into clinical trials of Treg-supported weaning after allogeneic transplantation.
引用
收藏
页码:917 / 930
页数:14
相关论文
共 50 条
  • [41] Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
    Cummins, Katherine
    Gill, Saar
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1125 - 1147
  • [42] Chimeric antigen receptor T cells for acute myeloid leukemia
    Fetsch, Viktor
    Zeiser, Robert
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (01) : 28 - 35
  • [43] Chimeric antigen receptor T cells applied to solid tumors
    Zhou, Zhongguo
    Tao, Can
    Li, Jianting
    Tang, Johnny Cheuk-on
    Chan, Albert Sun-chi
    Zhou, Yuanyuan
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [44] Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
    Maude, Shannon L.
    Frey, Noelle
    Shaw, Pamela A.
    Aplenc, Richard
    Barrett, David M.
    Bunin, Nancy J.
    Chew, Anne
    Gonzalez, Vanessa E.
    Zheng, Zhaohui
    Lacey, Simon F.
    Mahnke, Yolanda D.
    Melenhorst, Jan J.
    Rheingold, Susan R.
    Shen, Angela
    Teachey, David T.
    Levine, Bruce L.
    June, Carl H.
    Porter, David L.
    Grupp, Stephan A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (16) : 1507 - 1517
  • [45] Chimeric antigen receptor T cells for acute lymphoblastic leukemia
    Frey, Noelle V.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S24 - S27
  • [46] Innovation and opportunity for chimeric antigen receptor targeted T cells
    Melenhorst, J. Joseph
    Levine, Bruce L.
    [J]. CYTOTHERAPY, 2013, 15 (09) : 1046 - 1053
  • [47] Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations
    Owusu, Kent A.
    Schiffer, Molly
    Perreault, Sarah
    [J]. AACN ADVANCED CRITICAL CARE, 2022, 33 (04) : 301 - 307
  • [48] Toxicities of chimeric antigen receptor T cells: recognition and management
    Brudno, Jennifer N.
    Kochenderfer, James N.
    [J]. BLOOD, 2016, 127 (26) : 3321 - 3330
  • [49] Toxicity management of chimeric antigen receptor T-cells
    Le Bourgeois, Arnandine
    [J]. BULLETIN DU CANCER, 2018, 105 : S188 - S197
  • [50] Pharmacology of Chimeric Antigen Receptor-Modified T Cells
    Song, Edward Z.
    Milone, Michael C.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021, 2021, 61 : 805 - 829